Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
December 06, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
December 04, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe
November 28, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018
November 26, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel
October 01, 2018 07:00 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018
September 25, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
September 05, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018
August 28, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
August 16, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of AC5™ Topical Gel (“AC5™”), today announced that new research...
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
July 20, 2018 07:30 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announced the...